{"id":809130,"date":"2025-02-05T08:38:38","date_gmt":"2025-02-05T13:38:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/"},"modified":"2025-02-05T08:38:38","modified_gmt":"2025-02-05T13:38:38","slug":"myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/","title":{"rendered":"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration"},"content":{"rendered":"
\n

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc<\/u><\/a>. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc.,<\/u><\/a> a leader in digital pathology solutions, have signed an agreement to integrate Myriad\u2019s advanced molecular diagnostic tests \u2014 Prolaris<\/u><\/a>\u00ae<\/u><\/sup><\/a> Prostate Cancer Test<\/u><\/a> and MyRisk<\/u><\/a>\u00ae<\/u><\/sup><\/a> Hereditary Cancer Test<\/u><\/a> \u2013 into Lumea\u2019s digital pathology platform, BxLink\u2122.<\/p>\n

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered directly within BxLink\u2019s intuitive platform. By replacing manual processes, the integration will reduce errors and aims to deliver molecular testing results to clinicians in an average of under 10 days after specimen collection.<\/p>\n

\u201cClinicians need ready access to molecular diagnostic tools at the point of care to improve cancer outcomes,\u201d said George Daneker, Jr., MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. \u201cProlaris \u2014 included in the recent NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer (NCCN Guidelines\u00ae<\/sup>)i<\/sup> \u2014 quantifies prostate cancer aggressiveness to guide treatment decisions at cancer diagnosis, while MyRisk evaluates 48 genes associated with hereditary cancer risk to guide treatments and identify risks to family members. This collaboration with Lumea ensures precision-based insights are delivered in a timely fashion when they\u2019re needed most to empower patients and providers to make informed decisions.\u201d<\/p>\n

\u201cThis integration simplifies workflows for physicians,\u201d said Jim Pack, CEO of Lumea. \u201cWith fewer clicks and reduced data entry, clinicians can seamlessly order Myriad\u2019s advanced tests, access actionable results within the platform they trust, and deliver personalized care. These insights can unlock advanced treatment options, targeted therapies, and clinical trials, driving improved patient outcomes.\u201d<\/p>\n

\n About Lumea<\/strong>
\n
Lumea is the U.S. leader in clinical digital pathology, processing the highest volume of primary digital diagnosis nationwide. With over a decade of expertise, its innovative tissue-handling technology and AI-driven workflows set a new standard of efficiency, quality, and standardization in cancer diagnostics. Trusted by over 50% of the U.S. urology market and spanning five continents, Lumea\u2019s solutions enhance tissue integrity, improve detection rates, and deliver measurable ROI. By placing patients at the core, Lumea is transforming pathology for a more precise and efficient future. Learn more at www.lumeadigital.com. Learn more at www.lumeadigital.com<\/u><\/a>.<\/p>\n

\n About Myriad Genetics<\/strong>
\n
Myriad Genetics is a leading genetic and genomic tumor testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com<\/u><\/a>.<\/p>\n

\n Safe Harbor Statement\u00a0 \u00a0<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company\u2019s collaboration with Lumea will streamline the ordering and delivery of molecular tests and that by replacing manual processes, the integration will reduce errors and aims to provide clinicians with timely molecular testing results\u2014 on average, in under 10 days after specimen collection\u2014to empower patients and providers to make informed decisions. These \u201cforward-looking statements\u201d are management\u2019s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the company\u2019s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company\u2019s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.\u00a0<\/p>\n

\n Investor Contact\u00a0<\/strong>
\n
Matt Scalo\u00a0
(801) 584-3532\u00a0
IR@myriad.com<\/u><\/a>\u00a0<\/p>\n

\n Media Contact\u00a0<\/strong>
\n
Kate Schraml
(224) 875-4493
PR@myriad.com<\/a>
<\/a>_____________________________<\/p>\n

\n i<\/sup> National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad\u2019s advanced molecular diagnostic tests \u2014 Prolaris\u00ae Prostate Cancer Test and MyRisk\u00ae Hereditary Cancer Test \u2013 into Lumea\u2019s digital pathology platform, BxLink\u2122. This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered directly within BxLink\u2019s intuitive platform. By replacing manual processes, the integration will reduce errors and aims to deliver molecular testing results to clinicians in an average of under 10 days after specimen … <\/p>\n

Continue reading “Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809130","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMyriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad\u2019s advanced molecular diagnostic tests \u2014 Prolaris\u00ae Prostate Cancer Test and MyRisk\u00ae Hereditary Cancer Test \u2013 into Lumea\u2019s digital pathology platform, BxLink\u2122. This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered directly within BxLink\u2019s intuitive platform. By replacing manual processes, the integration will reduce errors and aims to deliver molecular testing results to clinicians in an average of under 10 days after specimen … Continue reading "Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T13:38:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration\",\"datePublished\":\"2025-02-05T13:38:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/\"},\"wordCount\":725,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/\",\"name\":\"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=\",\"datePublished\":\"2025-02-05T13:38:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/","og_locale":"en_US","og_type":"article","og_title":"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - Market Newsdesk","og_description":"SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad\u2019s advanced molecular diagnostic tests \u2014 Prolaris\u00ae Prostate Cancer Test and MyRisk\u00ae Hereditary Cancer Test \u2013 into Lumea\u2019s digital pathology platform, BxLink\u2122. This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered directly within BxLink\u2019s intuitive platform. By replacing manual processes, the integration will reduce errors and aims to deliver molecular testing results to clinicians in an average of under 10 days after specimen … Continue reading \"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-05T13:38:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration","datePublished":"2025-02-05T13:38:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/"},"wordCount":725,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/","name":"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=","datePublished":"2025-02-05T13:38:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzA3NyM2NzM1OTEzIzIwMDc4ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myrisk-hereditary-cancer-tests-through-bxlink-integration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809130"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809130\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}